Literature DB >> 21252248

Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.

Louise Mannerås-Holm1, Fariba Baghaei, Göran Holm, Per Olof Janson, Claes Ohlsson, Malin Lönn, Elisabet Stener-Victorin.   

Abstract

CONTEXT: Studies of fibrinolysis/coagulation status in women with polycystic ovary syndrome (PCOS) are contradictory.
OBJECTIVES: The aim of the study was to investigate whether women with PCOS have disturbed circulating levels of fibrinolysis/coagulation markers and, if so, whether the disturbances are related to hemodynamics, metabolic variables, sex steroids, SHBG, lipids, and inflammatory variables in women with PCOS. DESIGN/MAIN OUTCOME MEASURES: Anthropometric variables, hemodynamics, circulating hemostatic and inflammatory markers, and serum lipid profile were measured in women with untreated PCOS (n = 74) and controls (n = 31).
RESULTS: After adjustments for age and body mass index (BMI), circulating plasminogen activator inhibitor 1 (PAI-1) activity and fibrinogen levels were higher in women with PCOS than controls; lipid profile, blood pressure, and levels of D-dimer, von Willebrand factor, factor VIII, tissue plasminogen activator, and inflammatory markers were comparable in the two groups. In multiple linear regression analyses including women with PCOS, low SHBG and high insulin predicted high PAI-1 activity (R(2) = 0.526; P < 0.001); elevated high-sensitivity C-reactive protein and soluble E-selectin in combination with heart rate predicted high fibrinogen (R(2) = 0.333; P < 0.001). Differences in PAI-1 activity were not significant after adjustments for age, BMI, SHBG, and insulin.
CONCLUSIONS: PCOS is characterized by a prothrombotic state, as reflected by increased PAI-1 activity and fibrinogen, without signs of dyslipidemia or a proinflammatory state. Low SHBG and high insulin may partly explain the BMI-independent difference in PAI-1 activity between women with PCOS and controls. High-sensitivity C-reactive protein and E-selectin may be involved in regulating fibrinogen in PCOS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252248     DOI: 10.1210/jc.2010-2279

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

Review 2.  Meta-analysis of therapeutic efficacy and effects of integrated traditional Chinese and Western medicine on coagulation and fibrinolysis system in patients with threatened abortion and polycystic ovary syndrome.

Authors:  Xueli Chen; Chong Tao; Jingyi Wang; Baochang He; Jinbang Xu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome: a preliminary study.

Authors:  Yu Shan; Aiming Wang; Ying Sun; Wen Jiang; Baosen Pang; Zhiyuan An; Xin Du; Wei Wang; Zhongwei Huang
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

4.  Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

5.  Transient neonatal Behcet's disease.

Authors:  Marilina Antonelou; Nirit Braha
Journal:  BMJ Case Rep       Date:  2013-02-06

6.  Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008.

Authors:  Ekwutosi M Okoroh; W Craig Hooper; Hani K Atrash; Hussain R Yusuf; Sheree L Boulet
Journal:  Am J Obstet Gynecol       Date:  2012-08-10       Impact factor: 8.661

7.  C-Reactive Protein, Fibrinogen, Leptin, and Adiponectin Levels in Women with Polycystic Ovary Syndrome.

Authors:  Cagdas Ozgokce; Erkan Elci; Recep Yildizhan
Journal:  J Obstet Gynaecol India       Date:  2020-08-19

8.  DIA proteomics analysis through serum profiles reveals the significant proteins as candidate biomarkers in women with PCOS.

Authors:  Ying Yu; Panli Tan; Zhenchao Zhuang; Zhejiong Wang; Linchao Zhu; Ruyi Qiu; Huaxi Xu
Journal:  BMC Med Genomics       Date:  2021-05-09       Impact factor: 3.063

Review 9.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

10.  Comparison of 25-hydroxyvitamin D and Calcium Levels between Polycystic Ovarian Syndrome and Normal Women.

Authors:  Ashraf Moini; Nooshin Shirzad; Marzieh Ahmadzadeh; Reihaneh Hosseini; Ladan Hosseini; Shahideh Jahanian Sadatmahalleh
Journal:  Int J Fertil Steril       Date:  2015-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.